Press Releases

Berlin, 5 September 2017 – The biopharmaceutical company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) will present two posters on its lead compound, the immunotherapeutic agent lefitolimod, at the European Society for...

• Binding term sheet offers the potential to translate into a licensing deal for lefitolimod – homing in on key objective • MOLOGEN to receive upfront and milestone payments, royalties and an equity investment under the final contract • Strong...

• Results from the TEACH (HIV) and IMPULSE (small cell lung cancer) clinical trials with lefitolimod • Completion of patient recruitment for the IMPALA pivotal study (colorectal cancer) • Promising results obtained from pre-clinical combination...

The biopharmaceutical company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) announced the key results of the extension phase of the exploratory phase Ib/IIa TEACH trial to evaluate lefitolimod in HIV-positive (HIV:...

Berlin, 15 May 2017 – The biopharmaceutical company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) has achieved the recruitment goal with the inclusion of currently 540 patients for the pivotal IMPALA study in...

• Ongoing implementation of the “Next Level” corporate strategy • Funding secured until the start of 2018 through additional capital measure • Further progress in clinical studies with lead product lefitolimod • Preparations for possible...

- Clinically relevant subgroups benefit from the treatment with lefitolimod in this study - Results are indicative for the further development of lefitolimod in SCLC